ImmuPharma PLC (LON:IMM) PT Raised to GBX 181 at Northland Securities

ImmuPharma PLC (LON:IMM) had its price objective upped by research analysts at Northland Securities from GBX 171 ($2.23) to GBX 181 ($2.36) in a research report issued on Friday, June 30th. The firm presently has a “buy” rating on the stock. Northland Securities’ price target suggests a potential upside of 212.74% from the company’s current price.

Separately, Panmure Gordon restated a “buy” rating and set a GBX 100 ($1.30) price target on shares of ImmuPharma PLC in a report on Thursday, April 20th.

Shares of ImmuPharma PLC (IMM) traded up 0.216% during midday trading on Friday, reaching GBX 57.875. The company had a trading volume of 39,156 shares. ImmuPharma PLC has a 52 week low of GBX 31.44 and a 52 week high of GBX 70.32. The stock has a 50-day moving average of GBX 54.17 and a 200 day moving average of GBX 54.05. The firm’s market capitalization is GBX 76.70 million.

ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/07/28/immupharma-plc-lonimm-price-target-raised-to-gbx-181-at-northland-securities-updated-updated-updated.html.

ImmuPharma PLC Company Profile

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents.

Receive News & Ratings for ImmuPharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply